RevealDx
by RevealDx
· Based in United States →
— Dramatically improve lung cancer outcomes using non-invasive diagnosis.
Reimbursable by medicare for us clinical use at a rate of $650.
Overview
RevealAI-Lung by RevealDx is an AI-powered Computer-Aided Diagnosis (CADx) software designed to assist radiologists in evaluating incidental lung nodules on chest CT scans.
- What it does: The software generates a Malignancy Similarity Index (mSI), a quantitative score that characterizes a detected lung nodule and provides a risk assessment. This score is intended to support clinicians in making informed follow-up recommendations.
- Who it is for: RevealAI-Lung is primarily for radiologists and other healthcare professionals involved in lung nodule assessment and lung cancer screening programs.
- How it fits a clinical or practice workflow: A notable feature is its direct integration into Picture Archiving and Communication Systems (PACS), aiming to minimize disruption to existing routines. The mSI can be computed with a single click and results are displayed within seconds, allowing for integration into the radiology report.
- Notable capabilities: The software utilizes real-world data from the National Lung Screening Trial (NLST) as a reference population for its scoring. It is designed to be generalizable across different exam types and patient populations. RevealDx has also partnered with other companies for distribution and integration, including Sirona Medical and Riverain Technologies.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered lung nodule characterization
- CT scan analysis
- Differentiation of benign vs. malignant nodules
- Quantitative and qualitative data insights
- Integration into clinical workflows
- Supports diagnostic confidence
- Non-invasive assessment
Use Cases
- Early lung cancer detection
- Lung nodule management
- Reducing unnecessary invasive procedures
- Enhancing diagnostic accuracy in radiology
- Supporting treatment planning in oncology
Details
| Category | Clinical Decision Support & Reference, Lab & Diagnostics, Radiology & Imaging AI |
| Pricing | Reimbursable by medicare for us clinical use at a rate of $650. |
| Deployment | Integrates directly into PACS. |
| Mobile App | None |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Unknown |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Pulmonology, Radiology, Thoracic Surgery |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate RevealDx
No press coverage or publications on file yet.
Know of some? Suggest an edit →
Videos
Product demos, reviews, and walkthroughs for RevealDx.
JACR Paper Overview RevealDx
RevealDx
Beyond Detection: How RevealDX Uses AI to Tackle Lung Cancer (ft. CEO Chris Wood)
HealthTech Remedy
RevealAI-Lung Demonstration
RevealDx
RevealDX at AngelMD Pitch Club (September 28, 2021)
AngelMD Inc
RevealAI Lung
RevealDx
Episode 60: How to make money from medical AI, with Chris Wood, CEO of RevealDX
Felix Beacher
Frequently Asked Questions
RevealDx is a Seattle-based software company that provides AI-enabled lung cancer decision support software, specifically RevealAI-Lung. It characterizes incidental lung nodules by generating a Malignancy Similarity Index (mSI) score, which helps radiologists assess the likelihood of cancer and make more informed follow-up recommendations.
RevealAI-Lung has received FDA clearance in the US (January 2026) and MDR Certification in Europe (November 2025). It also has market authorization for clinical use in Canada, Australia, New Zealand, and is registered for use in the UK.
RevealAI-Lung is designed for single-click operation and integrates directly into Picture Archiving and Communication Systems (PACS), minimizing disruption to radiologists' routines. Key features include generating the mSI score, providing actionable radiomic insights, and supporting consistent follow-up recommendations.
Benefits include accelerating diagnosis, reducing false positives, potentially identifying malignant nodules earlier, and decreasing unnecessary procedures, which can lead to significant cost savings. While the software is validated on over 1,500 patients, it is intended to complement other clinical information rather than provide an independent diagnosis.
In the US, RevealAI-Lung is reimbursable by Medicare under the Outpatient Prospective Payment System (OPPS) using codes 0721T and 0722T, at a rate of approximately $650. Specific pricing plans for direct purchase are not publicly detailed, but the company emphasizes significant cost savings through reduced unnecessary procedures.
Yes, there are several alternatives in the market. Some companies offering AI-powered lung nodule solutions include contextflow (ADVANCE Chest CT), Riverain (ClearRead CT), Qure AI (qCT-Lung & qCT LN Quant), Coreline (AVIEW LCS), and DeepHealth (Chest Suite). Other general EHR and practice management alternatives mentioned include Epic, Carepatron, and ModMed.
RevealDx states that its software has been extensively validated in clinical trials and years of research, including validation on over 1,500 patients from various cohorts. Studies have demonstrated its ability to improve early cancer detection rates and reduce false positives.
Suggest an Edit → | Report an issue
| Last Verified: 2026-08-24 | First Added: 2026-08-23



